GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Price-to-Owner-Earnings

Amplia Therapeutics (ASX:ATX) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-06), Amplia Therapeutics's share price is A$0.072. Amplia Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Amplia Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ASX:ATX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.81
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-06), Amplia Therapeutics's share price is A$0.072. Amplia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was A$-0.02. Therefore, Amplia Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-06), Amplia Therapeutics's share price is A$0.072. Amplia Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was A$-0.02. Therefore, Amplia Therapeutics's PE Ratio without NRI for today is At Loss.


Amplia Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Amplia Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Price-to-Owner-Earnings Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amplia Therapeutics Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amplia Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Amplia Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Price-to-Owner-Earnings falls into.



Amplia Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Amplia Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.072/-0.03
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics  (ASX:ATX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Amplia Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics (ASX:ATX) Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (ASX:ATX) Headlines

No Headlines